Fomivirsen

L Grillone, R Lieberman - Kucers' The Use of Antibiotics, 2017 - taylorfrancis.com
Fomivirsen sodium (Vitravene, IONIS Pharmaceuticals, Carlsbad, CA, and Novartis
Pharmaceuticals, Switzerland), is a 21-base phosphorothioate DNA antisense
oligonucleotide developed for intravitreal injection as a treatment for CMV retinitis. The
oligonucleotide is designed to be complimentary to a cytomegalovirus (CMV) messenger
RNA (mRNA) that encodes for the major immediate early (IE2) region proteins of this virus. It
was the first to be developed in its class of a group of highly specific and novel therapeutics …

Fomivirsen

CM Perry, JAB Balfour - Drugs, 1999 - Springer
Abstract▴ Fomivirsen (ISIS 2922) is an antisense oligonucleotide which specifically inhibits
replication of human cytomegalovirus. It achieves this by binding to complementary
sequences on messenger RNA transcribed from the major immediate-early transcriptional
unit of the virus. It is being developed for the treatment of cytomegalovirus retinitis.▴ Mean
maximum retinal concentrations of fomivirsen occurred∼ 2 days after a single intravitreal
injection in monkeys. The elimination half-life of fomivirsen (after a single 115μg dose) in …

Fomivirsen: clinical pharmacology and potential drug interactions

RS Geary, SP Henry, LR Grillone - Clinical pharmacokinetics, 2002 - Springer
Fomivirsen sodium is a 21-base phosphorothioate oligodeoxynucleotide complementary to
the messenger RNA of the major immediate-early region proteins of human
cytomegalovirus, and is a potent and selective antiviral agent for cytomegalovirus retinitis.
Following intravitreal administration, fomivirsen is slowly cleared from vitreous with a half-life
of approximately 55 hours in humans. Preclinical studies show that fomivirsen distributes to
retina and is slowly metabolised by exonuclease digestion. Clearance from retina was …